TY - JOUR
T1 - Performance of the cepheid CT/NG Xpert rapid PCR test for detection of Chlamydia trachomatis and Neisseria gonorrhoeae
AU - Gaydos, Charlotte A.
AU - Van Der Pol, Barbara
AU - Jett-Goheen, Mary
AU - Barnes, Mathilda
AU - Quinn, Nicole
AU - Clark, Carey
AU - Daniel, Grace E.
AU - Dixon, Paula B.
AU - Hook, Edward W.
AU - Davis, Thomas
AU - Pancholi, Preeti
AU - Kerndt, Peter
AU - Horner, Patrick
AU - Marrazzo, Jeanne
AU - De Burgh-Thomas, Andrew
AU - Castro, José
AU - Ferguson, Dorothy
AU - Meyer, Michelle
AU - Philip, Susan
AU - Van Der Pol, Bobbie
AU - Thompson, Melanie
AU - Taylor, Stephanie
AU - Ronk, David
AU - Fine, Paul
AU - Bachman, Laura
AU - Mayne, Donna
AU - Dietz, Craig
AU - Toevs, Kim
AU - Gettings, Nikole
AU - Gall, Stanley
AU - Patel, Rajul
AU - Ross, Jonathan
AU - Brooks, Latina
AU - Hazan, Lydie
AU - Clarke, Patrick
AU - Groom, Robert
AU - Ackerman, Ronald
AU - Anduczyk, Eugene
AU - Mathews, Anakutty
AU - Blank, Stephen
AU - Harris, Lisa
AU - Tidings, Albert
AU - Moore, Philippa
AU - Alexander, Samuel
AU - Spurrell, Timothy
PY - 2013/6
Y1 - 2013/6
N2 - Tests for Chlamydia trachomatis and Neisseria gonorrhoeae, which can provide results rapidly to guide therapeutic decision-making, offer patient care advantages over laboratory-based tests that require several days to provide results.Wecompared results from the Cepheid GeneXpert CT/NG (Xpert) assay to results from two currently approved nucleic acid amplification assays in 1,722 female and 1,387 male volunteers. Results for chlamydia in females demonstrated sensitivities for endocervical, vaginal, and urine samples of 97.4%, 98.7%, and 97.6%, respectively, and for urine samples from males, a sensitivity of 97.5%, with all specificity estimates being ≥99.4%. Results for gonorrhea in females demonstrated sensitivities for endocervical, vaginal, and urine samples of 100.0%, 100.0%, and 95.6%, respectively, and for urine samples from males, a sensitivity of 98.0%, with all estimates of specificity being ≥99.8%. These results indicate that this short-turnaround-time test can be used to accurately test patients and to possibly do so at the site of care, thus potentially improving chlamydia and gonorrhea control efforts.
AB - Tests for Chlamydia trachomatis and Neisseria gonorrhoeae, which can provide results rapidly to guide therapeutic decision-making, offer patient care advantages over laboratory-based tests that require several days to provide results.Wecompared results from the Cepheid GeneXpert CT/NG (Xpert) assay to results from two currently approved nucleic acid amplification assays in 1,722 female and 1,387 male volunteers. Results for chlamydia in females demonstrated sensitivities for endocervical, vaginal, and urine samples of 97.4%, 98.7%, and 97.6%, respectively, and for urine samples from males, a sensitivity of 97.5%, with all specificity estimates being ≥99.4%. Results for gonorrhea in females demonstrated sensitivities for endocervical, vaginal, and urine samples of 100.0%, 100.0%, and 95.6%, respectively, and for urine samples from males, a sensitivity of 98.0%, with all estimates of specificity being ≥99.8%. These results indicate that this short-turnaround-time test can be used to accurately test patients and to possibly do so at the site of care, thus potentially improving chlamydia and gonorrhea control efforts.
UR - http://www.scopus.com/inward/record.url?scp=84878517141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878517141&partnerID=8YFLogxK
U2 - 10.1128/JCM.03461-12
DO - 10.1128/JCM.03461-12
M3 - Article
C2 - 23467600
AN - SCOPUS:84878517141
SN - 0095-1137
VL - 51
SP - 1666
EP - 1672
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 6
ER -